Highlights

  • Vitura Health confirmed its former CEO has commenced legal proceedings against the company.
  • The proceedings relate to the cessation of the former CEO’s employment in January 2026.
  • The allegations concern general protections provisions under the Fair Work Act 2009.
  • Vitura stated that all contractual and statutory entitlements were paid in full.
  • The company said it believes its actions were lawful and aligned with Shareholder expectations.
  • Vitura intends to seek an expedited handling of the proceedings.

Vitura Health Limited (ASX:VIT) has confirmed that its former Chief Executive Officer, Mr Geoff Cockerill, has initiated legal proceedings against the company in the Federal Circuit and Family Court of Australia.

According to the company’s ASX announcement released on 20 May 2026, the proceedings relate to the cessation of Mr Cockerill’s employment and associated matters following the termination of his role in January 2026.

Shares of Vitura Health Limited traded at AUD 0.037 during the afternoon Trading session on 20 May 2026, up 2.78% for the day, although the stock remains down 47.14% over the past year.

Company Says Employment Ended Under Contract Terms

Vitura stated that Mr Cockerill’s employment ended in January 2026 in accordance with the terms outlined within his employment contract.

The company also said that all contractual and statutory obligations relating to the cessation of employment were fulfilled in full, including payment in lieu of notice.

According to the announcement, the proceedings involve allegations that the company breached general protections provisions under the Fair Work Act 2009.

The company did not disclose further details regarding the specific allegations raised within the proceedings.

Vitura States It Intends to Defend the Matter

In its statement, Vitura Health Limited said it remains confident that its actions concerning the termination of Mr Cockerill’s employment were lawful and appropriate.

The company also stated that its actions were consistent with both contractual and statutory obligations and aligned with shareholder expectations.

Vitura indicated that it intends to seek an expedited process for dealing with the proceedings and confirmed that it reserves all rights in relation to the matter.

The announcement was authorised for release by the company’s board.

Focus on Digital Health and Telehealth Operations

Beyond the legal update, Vitura continues operating a diversified digital health Business across multiple healthcare and medicinal cannabis-related segments.

The company operates several businesses and platforms through its subsidiaries, including telehealth services, medicinal cannabis clinics, software-integrated healthcare systems and pharmaceutical distribution operations.

Its broader operations span prescription management, patient consultation services, healthcare software systems and therapeutic product distribution.

Vitura’s business structure includes both wholly owned subsidiaries and joint venture interests across several healthcare-related platforms.

Canview Platform Remains a Core Business Component

One of Vitura’s key operating businesses is Canview, which the company describes as an integrated healthcare ecosystem serving doctors, pharmacists, suppliers and patients.

The platform supports medicinal product distribution and prescription management workflows while integrating several software-as-a-service (SaaS) systems, including inventory management, analytics, invoicing and customer management tools.

According to the company, the Canview ecosystem currently supports approximately 4,700 Australian pharmacies with active platform accounts.

The platform enables doctors to integrate patient management systems directly into prescription workflows, while patients can access prescriptions and manage treatment through associated applications.

Vitura stated that the Canview platform has been designed to improve operational efficiency and compliance across medicinal treatment workflows.

Medicinal Cannabis Distribution and Telehealth Presence

Vitura Health Limited continues maintaining a significant presence in Australia’s medicinal cannabis sector through multiple businesses and healthcare platforms.

The company’s operations include Burleigh Heads Cannabis, Candor Medical, CDA Clinics and Cannadoc Health, all of which support medicinal cannabis consultations and patient access services through telehealth channels.

Vitura also holds an Equity interest in Flora Holdings Pty Ltd, which operates medicinal cannabis clinics under the Releaf Brand.

These businesses provide nationwide consultation services and prescription access pathways for patients seeking medicinal cannabis treatment and related healthcare services.

The company stated that its infrastructure includes distribution centres located in Melbourne and the Gold Coast, which support regulated product distribution activities.

Expansion Into Broader Healthcare and Psychedelic Markets

Alongside medicinal cannabis operations, Vitura has expanded into other healthcare and therapeutic sectors.

The company owns Doctors on Demand, a nationwide telehealth platform providing healthcare services including general consultations, urgent care, pathology referrals, medical certificates and specialist referrals.

Doctors on Demand operates on a 24-hour basis throughout the year and services both business-to-consumer and business-to-business healthcare channels.

Vitura also holds a 50% interest in Cortexa Pty Ltd, a joint venture with Canadian-based PharmAla Biotech.

Cortexa focuses on psychedelic-related products and aims to Supply GMP-grade MDMA and psilocybin products for therapeutic and research applications within Australia.

The company indicated that its digital healthcare platform structure may support the integration of additional healthcare and specialty therapeutic opportunities over time.

Regulatory and Compliance Environment Remains Important

As a healthcare-focused company operating across medicinal cannabis, telehealth and therapeutic product distribution, Vitura operates within a heavily regulated industry environment.

Businesses within these sectors are generally subject to healthcare regulations, licensing requirements, patient privacy obligations and pharmaceutical compliance standards.

Employment-related legal matters can also attract attention within publicly listed healthcare companies due to governance, compliance and operational oversight considerations.

Vitura has not indicated that the proceedings are expected to impact ongoing operations at this stage.

Corporate Governance and Shareholder Focus

The company stated in its announcement that its actions relating to the former CEO’s employment cessation were aligned with shareholder expectations.

Corporate governance practices and executive Leadership transitions often remain closely monitored by investors, particularly in listed healthcare and technology businesses operating within evolving regulatory sectors.

Vitura’s latest announcement was limited to confirming the proceedings and outlining the company’s position regarding the matter.

No financial impact estimates or additional legal guidance were disclosed alongside the update.

About Vitura Health

Vitura Health Limited is an ASX-listed digital health company operating across telehealth, medicinal cannabis, pharmaceutical distribution and healthcare software services.

Its business portfolio includes Canview, Doctors on Demand, Candor Medical, CDA Clinics, Cannadoc Health and interests in Releaf and Cortexa.

The company operates integrated digital healthcare systems supporting doctors, pharmacies, suppliers and patients across Australia.

Vitura also maintains infrastructure capable of distributing products under multiple regulated pharmaceutical schedules.

What This Means for Investors?

Vitura Health’s latest announcement confirmed the commencement of legal proceedings by its former Chief Executive Officer relating to the termination of employment earlier in 2026.

The company stated that all contractual and statutory obligations had been met and indicated that it intends to defend the matter while seeking an expedited process.

Although the update relates specifically to legal proceedings, investors may continue monitoring developments around governance, executive management and operational execution across Vitura’s broader digital healthcare and telehealth businesses.

The company continues operating across medicinal cannabis, telehealth and emerging therapeutic healthcare sectors through its various Subsidiary businesses and joint venture interests.